Product Description
Mechanisms of Action: pepsin Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Chile | Colombia | Germany | India | Korea | Mexico | Peru | Spain | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Almirall
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Heartburn
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR-OQR-14004879 |
ChiCTR-OQR-14004879 | N/A |
Recruiting |
Barrett Esophagus |
2018-10-30 |
|||
ChiCTR-IPR-15005905 |
ChiCTR-IPR-15005905 | N/A |
Not yet recruiting |
Gastritis |
2017-07-01 |
|||
2024-515381-14-00 |
M-00ALM-04 | P4 |
Recruiting |
Heartburn |
2026-11-01 |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/15/2025 |
News Article |
CPS Technologies Secures Fourth SBIR Contract of 2025 |
|
10/12/2023 |
PubMed |
The local microenvironment drives activation of neutrophils in human brain tumors. |
|
08/01/2022 |
PubMed |
Combining Liquid Oral Drugs with Thickener: Compatibility and Changes in Viscosity. |
|
05/23/2022 |
PubMed |
Structural Insight of MOFs under Combined Mechanical and Adsorption Stimuli. |